Before treatment with DAA drugs (Phase 1), MET plasma exposure did not differ between Groups 1 and 2 (Table 3), suggesting that the activity of OCT1/2 transporters does not change between different stages of liver fibrosis. This evidence concerns the gene SLC22A1 and Hepatic fibrosis.